Investigating the effects of specific tumor markers in lung cancer treatment
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
This study is looking at how certain genetic markers in people with non-small cell lung cancer might affect their response to a type of immunotherapy called PD-1 inhibitors, so we can better understand which patients could benefit the most from this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10894083 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain genetic markers, known as motif neoepitopes, affect the tumor microenvironment in patients with non-small cell lung cancer (NSCLC). By analyzing tumor samples from patients with specific HLA-B44 alleles, the study aims to uncover how these markers influence the effectiveness of PD-1 inhibitors, a type of immunotherapy. The research will utilize advanced techniques such as gene expression profiling and multiplex immunofluorescence to evaluate the immune response and cellular composition in tumors. This comprehensive approach seeks to identify which patients may benefit most from these treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have specific HLA-B44 genetic markers.
Not a fit: Patients without non-small cell lung cancer or those who do not have the HLA-B44 alleles may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for lung cancer patients, improving their chances of durable responses to therapy.
How similar studies have performed: Previous research has shown promising results in understanding the role of genetic markers in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Garon, Edward B — University of California Los Angeles
- Study coordinator: Garon, Edward B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.